Ontario has narrowed the circumstances in which it will publicly fund drug treatment outside Canada, following a court ruling that ordered OHIP to reconsider an Etobicoke cancer patient’s request for therapy in Florida.

The amended regulation says out-of-country drug treatment will generally qualify only when the drug is already publicly funded in Ontario but access here is temporarily unavailable or delayed.

A third rejection after court review

Alex Shved, a 37-year-old father of two with Stage 4 melanoma, sought public funding for tumour-infiltrating lymphocyte therapy in Florida. The treatment was estimated to cost approximately US$600,000.

His oncologist applied to OHIP, but the request and an initial reconsideration were denied. In September, a majority of an Ontario Divisional Court panel quashed the denial and ordered a new decision.

The court said OHIP had offered no real basis for its central reasoning: that funding the treatment abroad while it was being considered for Ontario coverage could undermine future price negotiations and the incentive for manufacturers to use Canada’s drug-review process.

According to The Canadian Press, OHIP has now rejected Shved’s request for a third time.

Province says change aligns law with policy

Ontario announced the Regulation 552 amendment on October 6. The government describes it as an alignment of the written regulation with an out-of-country drug policy it says has been in place since 2011.

The province says the restriction protects national drug-review and price-negotiation systems, supports consistent funding decisions and helps preserve affordable access to publicly funded medication.

Critics and Shved’s case raise a different concern: a treatment may be authorized in another country and urgently needed by an Ontario patient before the province has completed its own funding review.

Individual resolution still possible

Health Minister Sylvia Jones said the government is exploring a “mutually satisfactory resolution” in Shved’s individual case, The Canadian Press reported.

That statement leaves open the possibility of a case-specific outcome, but it does not change the broader regulation. The practical effect is that Ontarians generally cannot obtain provincial funding for a drug abroad simply because it is unavailable under Ontario’s current public plan.

The dispute illustrates the tension between urgent individual treatment decisions and a drug-funding system designed around population-wide review, bargaining and coverage rules.

Sources: The Canadian Press via Global News, published October 8 at 10:51 a.m. Eastern; Ontario Ministry of Health statement, October 6; The Canadian Press via CityNews: September court ruling.

AI-generated editorial illustration for The Northern Current. A conceptual treatment room and travel documents; this is not a photograph of Alex Shved or an Ontario hospital.